Medicines Formulary

Medicines A–Z

S

Drug name	NICE TAs	Comments
Somatropin injection	TA188 - Human growth hormone (somatropin) for the treatment of growth failure in children (review) TA64 - Growth hormone deficiency (adults) - human growth hormone
Sorafenib tablets	TA178 - Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma TA474 - Sorafenib for treating advanced hepatocellular carcinoma	National CDF list. Negative outcome - CDF funded.
Sotalol
Sotrovimab (Xevudy®)	TA878 - Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Spacer device		Able Spacer® - For use with all pressurised (aerosol) inhalers AeroChamber® Plus - For use with all pressurised (aerosol) inhalers Volumatic® - For use with Clenil Modulite®, Flixotide®, Seretide®, Serevent®, and Ventolin® inhalers
Spironolactone tablets		Retains potassium. Useful in liver cirrhosis and congestive heart failure with loop diuretic. Monitor potassium levels carefully.
Spironolactone tablets		Acne vulgaris in women that warrants treatment with antibiotics (off-label indication)
St Marks powder		Unlicensed
Stalevo tablets		ESCA
Staloral

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.